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Abstract
Aims—To examine long-term healthcare utilization and costs of patients with stable coronary 
artery disease (SCAD).
Methods and results—Linked cohort study of 94 966 patients with SCAD in England, 1 
January 2001 to 31 March 2010, identified from primary care, secondary care, disease, and death 
registries. Resource use and costs, and cost predictors by time and 5-year cardiovascular disease 
(CVD) risk profile were estimated using generalized linear models. Coronary heart disease 
hospitalizations were 20.5% in the first year and 66% in the year following a non-fatal 
(myocardial infarction, ischaemic or haemorrhagic stroke) event. Mean healthcare costs were 
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£3133 per patient in the first year and £10 377 in the year following a non-fatal event. First-year 
predictors of cost included sex (mean cost £549 lower in females), SCAD diagnosis (non-ST-
elevation myocardial infarction cost £656 more than stable angina), and co-morbidities (heart 
failure cost £657 more per patient). Compared with lower risk patients (5-year CVD risk 3.5%), 
those of higher risk (5-year CVD risk 44.2%) had higher 5-year costs (£23 393 vs. £9335) and 
lower lifetime costs (£43 020 vs. £116 888).
Conclusion—Patients with SCAD incur substantial healthcare utilization and costs, which varies 
and may be predicted by 5-year CVD risk profile. Higher risk patients have higher initial but lower 
lifetime costs than lower risk patients as a result of shorter life expectancy. Improved 
cardiovascular survivorship among an ageing CVD population is likely to require stratified care in 
anticipation of the burgeoning demand.
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Introduction
Improved survival coupled with a decline in the incidence of acute myocardial infarction 
(AMI)1,2 has dramatically changed the pattern of healthcare use over recent years.3,4 
Nowadays, patients with stable coronary artery disease (SCAD), including patients with 
stable angina and those who have become stable after acute coronary syndrome (ACS),5,6 
are older and living longer and so make greater use of healthcare resources. Patients with 
SCAD might be considered to have ‘fallen off the radar’ of clinical interest: no longer in 
cardiac rehabilitation [mainly offered to those immediately after AMI or coronary artery 
bypass grafting (CABG)], discharged from ongoing specialist care, and with suboptimal 
drug compliance, adherence, and persistence.7 Such patients, however, vary widely in their 
risk of subsequent AMI or coronary death (~10-fold, between top and bottom deciles of 
risk),8 which will clearly have differential resource implications.
While previous studies of resource use and cost have taken as a starting point AMI,9,10 there 
is a paucity of information about the contemporary use and associated costs of healthcare 
beyond the initial hospital stay. In addition, existing studies in the area have been limited in 
a number of ways. First, as a result of the nature of their samples, they are not population 
based and do not reflect contemporary and routine clinical practice.11 Second, they use 
overly simplistic models, typically restricting their analysis to a subset of SCAD index 
events and not evaluating how the pattern of healthcare resource use changes following a 
first post-SCAD myocardial infarction (MI) or stroke.9,10 Third, no study has evaluated 
resource utilization and costs according to baseline cardiovascular risk, despite the 
importance of this information in improving decision-making and ensuring more efficient 
use of limited healthcare resources. Fourth, longer term and particularly lifetime 
implications of SCAD have not been quantified.
These knowledge gaps have a number of important ramifications. They create uncertainty 
for those who need to forecast future care needs, restrain the research and development of 
new technologies and treatments for SCAD, and limit informed clinical decision-making. To 
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address these limitations, our study aimed to (i) determine healthcare utilization and the 
associated costs in the first year with SCAD and in the year following a first non-fatal event 
(i.e. AMI, ischaemic or haemorrhagic stroke), (ii) study predictors of costs in the first year 
of SCAD, and (iii) estimate the 5-year and lifetime costs among patients at low and high risk 
of subsequent events and coronary heart disease (CHD) death.
Methods
Data set and patient population
The ClinicAl research using Linked Bespoke studies and Electronic Records (CALIBER) e-
health database was the data resource for this study. CALIBER links patient records from 
four different data sources: Clinical Practice Research Database (CPRD), Myocardial 
Ischaemia National Audit Project (MINAP) registry, Hospital Episodes Statistics (HES), and 
the Office for National Statistics. The data of CPRD were used to obtain heart rate 
measurements, demographic variables, and other risk factors. Primary care practices that 
provide valuable data to CPRD and cover ~4% of UK population are representative in terms 
of demographic parameters such as gender, age, and ethnicity12,13 and overall mortality14 
and have been validated for epidemiological research. A description of the CALIBER 
approach has been presented elsewhere.15 Classification algorithms combining Read, 
International Classification of Disease 10 (ICD-10), drug, and procedure codes to define risk 
factors and endpoints are available at http://www.caliberresearch.org/portal/.
Eligible patients were those with a diagnosis of stable angina, patients with a diagnosis of 
ACS within the study period (unstable angina or AMI), or those with a diagnosis of CHD in 
which there is no further specification of whether it is angina or MI (other CHD). Study start 
date was calculated from the date of diagnosis of stable angina or other CHD or from 6 
months after an ACS or coronary intervention. The period of 6 months was chosen to 
differentiate long-term prognosis from the high-risk period that typically follows an ACS or 
revascularization. Diagnoses were identified in CPRD, HES, or MINAP records according to 
definitions given in the CALIBER data manual.15 Patients were only eligible for the study 
during the period they were actively registered at a CPRD practice that was collecting up-to-
standard data (according to CPRD measures of data quality and completeness), with follow-
up ending if a patient transferred out of a CPRD practice. Full details of the cohort are 
available elsewhere.8
Healthcare utilization
Healthcare utilization extracted from the data set included primary care consultations, 
pharmaceutical prescriptions, inpatient stays, and diagnostic tests. Primary care 
consultations included all contacts between the patient and healthcare professionals captured 
in the CPRD data set. Prescription data were available from the CPRD data set and 
distinguished between drugs that were cardiovascular disease (CVD)-related and those that 
were not. Inpatient stays extracted from HES were based on Health Resource Group (HRG) 
codes and defined as CHD, CVD (including CHD and broader HRGs), or non-CVD related 
based on ICD-10 codes. Diagnostic tests as recorded in the primary care data set but not 
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outpatient consultations were also extracted, the latter being due to the absence of outpatient 
HES data linkage.
Costs
All costs were calculated from the perspective of the UK National Health Service (NHS) in 
pound sterling based on 2011/12 prices. Costs were calculated by combining healthcare 
utilization data from CALIBER with associated unit costs that were taken from published 
UK sources.16-18 For hospitalizations, costs are calculated based on finished consultant 
episodes in HES. Costs are presented in terms of total healthcare costs (all costs incurred), 
CHD costs (all CHD-related hospitalization costs, CVD-related drugs, and all primary care 
and diagnostic costs), and CVD costs (all CVD-related hospitalization costs, CVD-related 
drugs, and all primary care and diagnostic costs).
Analytical methods
Estimates of healthcare utilization and costs were calculated for the first year in the SCAD 
cohort and the first year following a non-fatal event during the follow-up period (AMI, 
ischaemic or haemorrhagic stroke) with results reported as means and standard deviations, 
with medians and interquartile ranges reported in the appendices. Observations that were 
right censored for any reason other than mortality (i.e. those for which the data are 
incomplete for the year of interest, either first year with SCAD or first year following an 
event, but the reason for incompleteness was not death) were excluded from the analysis.
A generalized linear model with a log link and gamma distribution was used to estimate the 
impact of baseline covariates on costs in the first year in the SCAD cohort to account for the 
non-linear impact of covariates and the right skewness in cost data. Covariates were based 
on those used by Rapsomaniki et al.,8 which developed a prognostic model for SCAD 
patients, on the assumption that predictors of costs were likely linked to prognostic 
indicators. The covariates included the baseline diagnosis for entry to SCAD, co-
morbidities, age, gender, smoking status, and biomarkers. Models were fitted on five 
multiply-imputed data sets and estimates combined using Rubin’s rules.19 The impact of 
covariates has been transformed back onto the natural scale to allow for ease of 
interpretation.
Panel data methods with time invariant covariates were used to estimate patient costs over 
each 90-day period. Also estimated were the impact of events (non-fatal AMI, ischaemic and 
haemorrhagic stroke, CVD- and non-CVD-related death) on the costs in the period of the 
event and subsequent periods if the event was non-fatal. These costs were then combined 
with a state transition Markov model to estimate costs over a longer period. The model 
estimated the probabilities of, and mean times to, the first events of non-fatal AMI, 
ischaemic or haemorrhagic stroke, CVD- and non-CVD-related death, and subsequent CVD 
or non-CVD death following a non-fatal first event. These estimates were conditional on 
baseline covariates and were inferred from patient-level costs, covariates, survival, and 
events experienced. Full details of this model are available elsewhere with a brief description 
given in the appendix.20 For the purpose of this article, the results of costs over time are 
presented for patients based on average covariate patterns for the 5-year risk deciles of a 
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cardiovascular event. Discounted costs are also presented using a discount rate of 3.5% per 
annum.21
Results
Cohort
In total, 94 966 patients were identified who met the inclusion criteria, of which 44% were 
female. The mean age of men and women included were 67 and 72 years, respectively. For 
the primary SCAD diagnosis, 47.4% of patients had stable angina, 13.5% unstable angina, 
6.7% ST-elevation MI (STEMI), 9.7% non-STEMI (NSTEMI), and 22.6% had CHD not 
otherwise specified. Full details of the cohort can be found in Appendix Table A1.
Figure 1 summarizes the SCAD cohort and the patient numbers used for each analysis.
Healthcare utilization
Table 1 reports healthcare utilization in the first year in the SCAD cohort and in the first year 
following a non-fatal event during the follow-up period (AMI, ischaemic or haemorrhagic 
stroke). In the first year in the SCAD cohort, 20.5% of patients (n = 17 532) were 
hospitalized for CVD, and those who were hospitalized had a mean 1.9 stays (spells) in 
hospital with a mean length of stay of 4.6 days. In the year following a non-fatal event 
during follow-up, 66% of patients (n = 4354) were hospitalized for CHD. These patients 
spent a mean of 2.2 stays in hospital with a mean length of stay of 6.5 days. In the first year 
in SCAD, patients had a mean of 10.8 primary care appointments, and this increased to 13.7 
in the first year following a non-fatal event. In the first year of SCAD, 88.2% of patients 
were taking cardiovascular medication, which decreased to 83.6% in the year following a 
non-fatal event. In the first year of SCAD, 5.7% of patients had a revascularization 
procedure, increasing to 13.5% of patients in the first year following a non-fatal event.
Costs
Table 2 reports costs for hospitalizations, primary care appointments, diagnostic tests, and 
drugs in patients in the first year in the SCAD cohort, and in the first year following a non-
fatal event during follow-up (MI, ischaemic or haemorrhagic stroke). The mean total 
healthcare costs in the first year in the SCAD cohort were £3133 per patient, of which 56.8% 
(£1780) and 70.2% (£2199) were related to CHD and CVD, respectively. This estimate 
increased to £10 377 per patient in the year following a non-fatal event during follow-up, of 
which 66.2% (£6869) and 85.9% (£8916) were related to CHD and CVD, respectively. The 
majority of healthcare costs were driven by hospitalizations (64.4% in the first year in the 
SCAD cohort and 84.2% in the year following a non-fatal event during follow-up).
Cost predictors in the first year in the stable coronary artery disease cohort
Figure 2 presents the results of the regression analysis showing the incremental costs 
associated with different covariates and the associated 95% confidence intervals (CI) for the 
first year in the SCAD cohort. Non-CVD-related co-morbidities had the largest impact on 
costs, with a history of renal disease associated with the largest increment of £1998 per 
patient (95% CI £1715–£2297). A history of heart failure resulted in an additional cost of 
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£802 per patient (95% CI £683–£920). Of the baseline diagnoses for entry to the SCAD 
cohort, NSTEMI had the largest impact on cost with those patients with NSTEMI costing an 
additional £656 per patient (95% CI £473–£848) when compared with those with stable 
angina. Females were significantly less costly than males, being female was associated with 
a cost decrement of £549 per patient (95% CI −£638 to −£457). Figures A1 and A2 in the 
appendix present the same results for CVD- and CHD-related costs, respectively.
Estimated 90-day period and event costs
Tables A4, A5, and A6 in the appendix provide estimates of total healthcare costs, CVD-
related costs, and CHD-related costs, respectively, for a 90-day period based on a range of 
baseline characteristics. The tables also show the incremental costs in the period of an event 
and in subsequent periods for non-fatal events. For example, the background total healthcare 
costs for a male, mean age 69 years, with no co-morbidities would be £341 in the first 90 
days, increasing by £10 for each subsequent 90-day period. If the patient had a non-fatal 
AMI, he would incur an incremental cost (on top of the normal period cost of £372) of 
£5028 in the 90 days following the AMI with the incremental costs decreasing in subsequent 
trimesters until 360 days after which there is an incremental cost of £521 per 90 days 
suggesting significant ongoing lifetime costs of events. Also of note, the incremental costs in 
the period of death from CVD- and non-CVD-related causes were £2008 and £2240, 
respectively.
Estimated costs over time for stable coronary artery disease
Table 3 presents estimates of 5-year and lifetime costs (total and CVD related, undiscounted 
and discounted) of the representative patients for each risk group. The covariate profiles 
used are shown in Appendix Table A7.
A patient with SCAD representative of the lowest risk decile (5-year cardiovascular risk of 
3.5% and a life expectancy of 26.8 years) would have expected undiscounted costs of £9335 
over 5 years, of which 44.7 and 56.8% would be CHD and CVD related, respectively; and 
undiscounted lifetime costs of £116 888, of which 40.1 and 61.5% would be CHD and CVD 
related, respectively. A representative patient of the highest risk decile (5-year 
cardiovascular risk of 44.2% and a life expectancy of 5.51 years) would have expected 
undiscounted costs of £23 391 over 5 years, of which 53.0 and 72.9% would be CHD and 
CVD related, respectively; and life-time undiscounted costs of £43 020, of which 51.9 and 
72.5% would be CHD and CVD related, respectively.
Figure 3 shows the predicted total, CVD-related, and CHD-related costs and the survival 
curves over a 25-year period for representative patients of risk deciles 1 (lowest risk), 4, 7, 
and 10 (highest risk). Higher risk patients with SCAD have higher initial costs, which are 
overtaken by the lower risk patients as a result of higher mortality in the higher risk groups 
resulting in less time to accrue costs (5-year survivorship differs from 98.4% in risk decile 1 
to 40.7% in risk decile 10; and 25-year survivorship differs from 58.2% in risk decile 1 to 
0.5% in risk decile 10).
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Discussion
This study addresses a fundamental gap in knowledge relevant to clinicians and 
policymakers: what is the clinical, health service, and cost burden associated with SCAD? 
Using data from a large, contemporary, and representative population of patients from the 
England with SCAD, the analysis has shown that substantial healthcare costs are likely to be 
incurred as a result of improved ACS survivorship and the ageing population. Moreover, 5-
year and lifetime costs vary according to CVD risk, which may be readily predicted from the 
baseline characteristics of patients that are routinely collected. High-risk patients have 
considerably higher costs over the initial 5 years but lower lifetime costs than lower risk 
patients as a result of shorter life expectancy.
Patients with SCAD might be considered to have ‘fallen off the radar’ of clinical interest. 
Current guidelines give little information about how frequently and where such patients 
should be followed up or if and how they should be risk stratified.5,6 Our results clearly 
highlight the unmet need and the shortfalls of current approaches—with high use of primary 
care and frequent hospitalizations, there are considerable ongoing costs. The number of 
primary care consultations, a mean of 10.8 per patient in the first year in the SCAD cohort, 
is higher than previous estimates for the overall population (5.5 per year).22 In the first year 
in the SCAD cohort, over a third of patients were hospitalized (and 20.5% for CHD 
reasons). This is substantially higher than recent estimates for the general population in one 
area of the UK (14.9%),23 and markedly higher than that in the general population for a 
similar age (23.4 and 21.2% of 60- to 74-year-old males and females, respectively, based on 
HES data).
Healthcare utilization is, however, insufficient as a metric of the impact on the healthcare 
system. It is also important to consider the cost imposed on the NHS associated with those 
resources as this indicates the value of resources that cannot be devoted to health-enhancing 
activities for other patients. Mean costs of £3133 in the first year in the SCAD cohort are 
much higher than those in patients without chronic conditions (£293), but comparable with 
other chronic conditions (e.g. diabetes £3036).23 Very high costs in the first year following a 
non-fatal event during follow-up (MI, ischaemic or haemorrhagic stroke) (£10 377) are 
reflective of the healthcare utilization required to treat that event.
Patients were stratified by risk to understand the costs accrued in greater detail. This higher 
resolution analysis allows the identification of where novel treatments and health service 
interventions have the greatest potential to be cost-effective. Non-CVD comorbidities were 
common and had a major influence on costs with e.g. renal disease resulting in a mean extra 
cost of £1998 per patient in the first year of SCAD. This is an important finding when the 
presence of multiple co-morbidities has been shown to increase costs23 yet clinicians tend to 
focus only on single diseases.24
The panel data analysis examined the average cost per 90-day period with the disease and 
also the costs of events. The estimated incremental cost of a non-fatal MI over 1 year (£7677 
ignoring mortality risk) was lower than some previous estimates from trial populations (e.g. 
among patients with stable angina the estimate of £9775 from the EUROPA trial).11 
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However, this lower estimate may be reflective of less intensive use of healthcare resources 
in non-trial settings and should provide a more accurate representation of costs of these 
events in routine clinical practice. Estimated stroke costs in the first year of the event (£8902 
for ischaemic and £10 477 for haemorrhagic stroke incremental to background costs) were 
similar to those seen in other studies. For example, the OXVASC study estimated mean total 
healthcare costs per patient in the first year following stroke at £10524.25
Furthermore, a study of costs in the first year of SCAD and the first year following an event 
is of limited use to decision-makers who require more detailed information on the long-term 
costs and consequences of SCAD. This can be seen from the panel data analysis, which 
suggested ongoing long-term costs as a result of non-fatal events. By estimating 5-year and 
lifetime costs by CVD risk group, it was possible to examine the long-term cost implications 
as a result of the disease and future events. In the shorter term of 5 years, which is shorter 
than the life expectancy of even the highest risk group (although survivorship in this group 
was only 40.7% at 5 years), costs increased with cardiovascular risk, and were largely driven 
by the high number of fatal and non-fatal events among these patients. Over a lifetime, 
however, patients in the lower risk groups eventually had substantially higher costs than 
higher risk patients, primarily driven by greater life expectancy and, therefore, costs being 
incurred over a much longer period. This is a key finding of our research: increased 
survivorship as well as an increasingly co-morbid and older population will result in 
significant future healthcare costs. In turn, this has implications for the cost and therefore the 
cost-effectiveness of established and new SCAD treatments.
Many studies have attempted to address the burden of disease in terms of health losses but 
fewer have examined the impact on financial costs of disease. Our research used SCAD as 
an exemplar in estimating resource use and costs from ‘real world’ electronic health record 
data. The methods used here could be readily applied to other chronic diseases to help 
produce evidence of their resource and cost implications to better inform clinicians and 
decision-makers. This would reduce uncertainty for those who need to forecast future care 
needs and allow for better focused research and development of new technologies and 
treatments for these chronic diseases as well as resulting in better informed clinical decision-
making.
Limitations
While our study has a number of strengths including the multi-source electronic health 
record linkage, there are a number of limitations. In addition to being censored at 2010, after 
which there have been further improvements in the care and survivorship of SCAD, a key 
weakness of this study was the exclusion of outpatient appointment costs that cannot 
currently be linked from HES. As a result, the total healthcare costs of this population are 
underestimated. Further disaggregation of primary care costs into CHD and CVD related 
was not possible and therefore in each category all primary care costs have been included 
and therefore are likely overestimated. The estimation of lifetime costs has also involved 
extrapolation over a longer time period than is currently observed in the CALIBER data. 
This extrapolation is subject to considerable uncertainty. The SCAD population is also 
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inherently heterogeneous, and there may be value in further disaggregation of the population 
in future research.
Conclusions
Using a multi-source electronic health record approach, this study provides, for the first 
time, estimates and predictors of contemporary national healthcare utilization and costs in 
the first year of SCAD and the first year following an event. It reveals that patients with 
SCAD incur substantial healthcare utilization and costs, which vary and may be predicted by 
5-year CVD risk profiles. While high-risk patients incur substantially higher costs over the 
short term (5 years), low-risk patients incur higher lifetime costs as a result of greater life 
expectancy. Improved cardiovascular survivorship and an ageing UK population will require 
stratified care in anticipation of the burgeoning economic demand. The methods used here 
could be readily applied to other chronic diseases to better inform clinical decision-making.
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Figure 1. Stable coronary artery disease cohort.
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Figure 2. Forest plot of incremental costs associated with covariates.
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Figure 3. Expected costs and survival over time for patients representative of risk deciles 1, 4, 7, 
and 10. CHD, coronary heart disease; CVD, cardiovascular disease; RG, risk decile.
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Table 1
Healthcare utilization in first year in the stable coronary artery disease cohort and first 
year following a non-fatal event during follow-up (myocardial infarction, ischaemic or 
haemorrhagic stroke)
Resource use in first year (n = 85 702) Resource in first year following an event (n = 
6599)
Mean (SD) Mean (SD)
Hospitalizations
 Hospitalized (%) 37.6 (0.484) 83.5 (0.371)
 Hospitalized for CVD (%) 27 (0.444) 80.2 (0.399)
 Hospitalized for CHD (%) 20.5 (0.403) 66 (0.474)
 Inpatient stays 0.875 (4.421) 2.364 (6.425)
 Inpatient stays for CVD 0.503 (2.545) 1.931 (5.284)
 Inpatient stays for CHD 0.343 (1.321) 1.434 (3.315)
With any hospitalization n = 32 242 n = 5512
 Inpatient stays 2.325 (6.971) 2.83 (6.935)
 Length of stay 6.717 (17.583) 14.857 (20.349)
With any hospitalization for CVD n = 23 160 n = 5291
 Inpatient stays for CVD 1.862 (4.631) 2.408 (5.803)
 Length of stay 7.516 (12.757) 15.541 (20.939)
With any hospitalization for CHD n = 17 532 n = 4354
 Inpatient stays for CHD 1.674 (2.51) 2.174 (3.88)
 Length of stay 4.579 (7.617) 6.515 (10.857)
Revascularizations
 Any revascularization (%) 5.7 (0.232) 13.5 (0.341)
 PCI (%) 3 (0.17) 9.1 (0.287)
 CABG (%) 2.9 (0.169) 5 (0.218)
Primary care consultations 10.768 (10.857) 13.671 (15.407)
Drugs
 Patients on any drugs (%) 91.3 (0.281) 85.1 (0.356)
 Patients on CVD drugs (%) 88.2 (0.322) 83.6 (0.37)
 Patients on anticoagulants (%) 8.7 (0.282) 14.7 (0.354)
 Patients on ACEi or ARB (%) 47.7 (0.499) 61.5 (0.487)
 Patients on anti-platelets (%) 65.6 (0.475) 76.3 (0.425)
 Patients on β-blockers (%) 46 (0.498) 50.1 (0.5)
 Patients on calcium channel blockers (%) 31.5 (0.464) 32.6 (0.469)
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Table 2
Costs in first year in the stable coronary artery disease cohort and in first year following 
an event during follow-up (myocardial infarction, ischaemic or haemorrhagic stroke)
Costs in first year (n = 85 702) Costs in first year following an event (n = 6599)
Mean (SD) Mean (SD)
Total costs
 Total cost (£) 3133 (6101) 10 377 (12 260)
 Total CVD cost (£) 2199 (4632) 8916 (10 930)
 Total CHD costs (£) 1780 (3686) 6869 (9467)
Hospitalizations
 Inpatient costs (£) 2018 (5632) 8744 (11 554)
 Inpatient CVD costs (£) 1487 (4493) 7957 (10 796)
 Inpatient CHD costs (£) 1067 (3548) 5910 (9338)
Primary care costs (£) 466 (463) 589 (629)
Diagnostic test costs (£) 141 (232) 228 (311)
Drugs
 All drug costs (£) 508 (1548) 816 (3135)
 CVD drug costs (£) 105 (113) 142 (175)
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